Literature DB >> 8915487

Assessing prognosis for high-grade soft-tissue sarcomas: search for a marker.

X Q Li1, S G Parkekh, A E Rosenberg, H J Mankin.   

Abstract

BACKGROUND: Although improved staging technology, limb-sparing surgery, and adjunctive radiation and chemotherapy have improved the outlook for patients with malignant soft-tissue tumors of the trunk and extremities, it is evident that we cannot predict which patients will develop distant metastases. Although local control is now frequently achieved, most series of high-grade soft-tissue sarcomas carry a mortality rate of > 50%.
METHODS: In a retrospective study of 93 patients with high-grade sarcomas treated between 1986 and 1992 for whom complete studies including size and volume measurements and DNA ploidy determinations as assessed by flow cytometry were available, a search for a marker for increased risk of metastasis or death was performed.
RESULTS: Grade of the lesion, sex, diagnosis, anatomical site, ploidic data (including mean DNA index and presence of an aneuploid peak), and treatment factors (including type of surgery, local recurrence, or radiation protocol) did not correlate with outcome. Age (younger patients did better), size (greatest diameter) and volume, and positive margins at surgery correlated with total survival.
CONCLUSIONS: The results of the study, although negative, point out that using anatomical site, diagnosis, or ploidic analysis offers little toward anticipating outcome, whereas the size of the tumor is important.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915487     DOI: 10.1007/bf02306088

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  36 in total

1.  Treatment of the patient with stage M0 soft tissue sarcoma.

Authors:  H D Suit; H J Mankin; W C Wood; M C Gebhardt; D C Harmon; A Rosenberg; J E Tepper; D Rosenthal
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

Review 2.  DNA cytometry of musculoskeletal tumors. A review.

Authors:  A Kreicbergs
Journal:  Acta Orthop Scand       Date:  1990-06

Review 3.  Progress in the recognition and treatment of soft tissue sarcomas.

Authors:  F R Eilber; J F Huth; J Mirra; G Rosen
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

Review 4.  Adjuvant chemotherapy in the treatment of soft-tissue sarcoma.

Authors:  W C Mertens; V H Bramwell
Journal:  Clin Orthop Relat Res       Date:  1993-04       Impact factor: 4.176

Review 5.  Management of extremity soft-tissue sarcomas.

Authors:  H G Rosenthal; R M Terek; J M Lane
Journal:  Clin Orthop Relat Res       Date:  1993-04       Impact factor: 4.176

Review 6.  Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience.

Authors:  I J Spiro; A E Rosenberg; D Springfield; H Suit
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

7.  DNA ploidy in soft tissue tumors: an evaluation of the prognostic implications in the different tumor types.

Authors:  W Mellin; A Niezabitowski; M Brockmann; J Ritter; P Wuisman; V Krieg
Journal:  Curr Top Pathol       Date:  1995

Review 8.  Principles of staging of soft-tissue sarcomas.

Authors:  T D Peabody; M A Simon
Journal:  Clin Orthop Relat Res       Date:  1993-04       Impact factor: 4.176

9.  Clinical applicability of human in vivo localized phosphorus-31 magnetic resonance spectroscopy of bone and soft tissue tumors.

Authors:  H J Hoekstra; W J Boeve; R L Kamman; E L Mooyaart
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

10.  Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors.

Authors:  T M Weiner; E T Liu; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

View more
  1 in total

1.  Prognostic role of Rb, p16, Cyclin D1 proteins in soft tissue sarcomas.

Authors:  Byoung Yong Shim; Jinyoung Yoo; Yeon-Soo Lee; Young Sun Hong; Hoon-Kyo Kim; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.